Status:
TERMINATED
Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
Hospira, now a wholly owned subsidiary of Pfizer
Conditions:
Sedation
Respiration, Artificial
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to test the hypothesis that time on the ventilator and ICU length of stay will be shorter in TAA patients given postoperative sedation with dexmedetomidine compa...
Detailed Description
Repair of thoraco-abdominal aortic aneurysms (TAA) is mostly performed in specialized centers. These centers report an operative mortality around 10%. In an analysis of 337 consecutive TAA, Cambria et...
Eligibility Criteria
Inclusion
- All Patients over age 18 undergoing non-emergent repair of type I-III TAA
Exclusion
- Pregnancy
- Patients with hepatic impairment (increase of ALT or AST three times normal)
- Patient taking clonidine or tricyclic antidepressants.
- Patients taking opioids or benzodiazepines chronically (\> 2 doses a day for \> 1 month)
- Patients with second or third degree heart block without a pacer
- Patients undergoing emergency repair of TAA
- Intraoperative cardiac arrest
- Intraoperative massive blood loss (\>10 l)
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00409344
Start Date
January 1 2007
End Date
January 1 2008
Last Update
September 22 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114